← All trials
NCT03389802
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 2, 2018
- Primary completion
- Sep 30, 2019
- Completion date
- Sep 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 45
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pediatric Brain Tumor ConsortiumLead sponsor
- Apexigen, Inc.Collaborator
- Memorial Sloan-Kettering Cancer CenterStudy chair
- St. Jude Children's HospitalCollaborator
- A Kids Brain Tumor CureCollaborator
- American Lebanese Syrian Associated CharitiesCollaborator
- Solving Kids’ CancerCollaborator
- National Cancer Institute (NCI)Collaborator
- Ty Louis Campbell FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.